Pifithrin-α provides neuroprotective effects at the level of mitochondria independently of p53 inhibition

Apoptosis

Volumn 19, Issue 12, 2014, Pages 1665-1677

  Neitemeier, Sandra ^a   Ganjam, Goutham K ^a   Diemert, Sebastian ^a   Culmsee, Carsten ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Mitochondria; Neuroprotection; Oxytosis; p53; Pifithrin

Indexed keywords

GLUTAMIC ACID; GLUTATHIONE; MESSENGER RNA; NEUROPROTECTIVE AGENT; PIFITHRIN ALPHA; PROTEIN BID; PROTEIN MDM2; PROTEIN NOXA; PROTEIN P21; PROTEIN P53; PUMA PROTEIN; SMALL INTERFERING RNA; APOPTOSIS REGULATORY PROTEIN; BENZOTHIAZOLE DERIVATIVE; PIFITHRIN; TOLUENE;

ANIMAL CELL; ARTICLE; CELL DEATH; CELL IMMORTALIZATION; CELL MEMBRANE DEPOLARIZATION; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; GENE SILENCING; HIPPOCAMPAL NEURONAL CULTURE; LIPID PEROXIDATION; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MOUSE; MTT ASSAY; NEUROPROTECTION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; TRANSCRIPTION INITIATION; UPREGULATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL MEMBRANE; DRUG EFFECTS; GENE INACTIVATION; GENETICS; HIPPOCAMPUS; HUMAN; METABOLISM; NERVE CELL; TUMOR CELL LINE; ULTRASTRUCTURE;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BENZOTHIAZOLES; CELL LINE, TUMOR; CELL MEMBRANE; GENE KNOCKOUT TECHNIQUES; GLUTAMIC ACID; HIPPOCAMPUS; HUMANS; LIPID PEROXIDATION; MITOCHONDRIA; NEURONS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; RNA, SMALL INTERFERING; TOLUENE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84941035894     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-014-1048-2     Document Type: Article

References (52)

1. Culmsee C, Landshamer S (2006) Molecular insights into mechanisms of the cell death program: role in the progression of neurodegenerative disorders. Curr Alzheimer Res 3(4):269-283
2. Mattson MP (1998) Modification of ion homeostasis by lipid peroxidation: roles in neuronal degeneration and adaptive plasticity. Trends Neurosci 21(2):53-57
3. Lin MT, Beal MF (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443(7113):787-795
4. Grohm J, Plesnila N, Culmsee C (2010) Bid mediates fission, membrane permeabilization and peri-nuclear accumulation of mitochondria as a prerequisite for oxidative neuronal cell death. Brain Behav Immun 24(5):831-838
5. Tobaben S, Grohm J, Seiler A, Conrad M, Plesnila N, Culmsee C (2011) Bid-mediated mitochondrial damage is a key mechanism in glutamate-induced oxidative stress and AIF-dependent cell death in immortalized HT-22 hippocampal neurons. Cell Death Differ 18(2):282-292
6. Galluzzi L, Blomgren K, Kroemer G (2009) Mitochondrial membrane permeabilization in neuronal injury. Nat Rev Neurosci 10(7):481-494
7. Zhang J, Cao Q, Li S, Lu X, Zhao Y, Guan J, Chen J, Wu Q, Chen G (2013) 3-hydroxybutyrate methyl ester as a potential drug against Alzheimer's disease via mitochondria protection mechanism. Biomaterials 34(30):7552-7562
8. Marques-Aleixo I, Oliveira PJ, Moreira PI, Magalhães J, Ascensão A (2012) Physical exercise as a possible strategy for brain protection: evidence from mitochondrial-mediated mechanisms. Prog Neurobiol 99(2):149-162
9. Checler F, da Costa CA (2014) p53 in neurodegenerative diseases and brain cancers. Pharmacol Ther 142(1):99-113
10. Tomasevic G, Shamloo M, Israeli D, Wieloch T (1999) Activation of p53 and its target genes p21WAF1/Cip1 and PAG608/Wig-1 in ischemic preconditioning. Mol Brain Res 70(2):304-313
11. Culmsee C, Mattson MP (2005) p53 in neuronal apoptosis. Biochem. Biophys. Res. Commun. 331(3):761-777
12. Vousden KH, Prives C (2009) Blinded by the light: the growing complexity of p53. Cell 137(3):413-431
13. Muller Patricia A J, Vousden KH (2013) p53 mutations in cancer. Nat Cell Biol 15(1):2-8
14. Xiang H, Hochman DW, Saya H, Fujiwara T, Schwartzkroin PA, Morrison RS (1996) Evidence for p53-mediated modulation of neuronal viability. J Neurosci 16(21):6753-6765
15. Culmsee C, Siewe J, Junker V, Retiounskaia M, Schwarz S, Camandola S, El-Metainy S, Behnke H, Mattson MP, Krieglstein J (2003) Reciprocal inhibition of p53 and nuclear factor-kappaB transcriptional activities determines cell survival or death in neurons. J Neurosci 23(24):8586-8595
16. Plesnila N, von Baumgarten L, Retiounskaia M, Engel D, Ardeshiri A, Zimmermann R, Hoffmann F, Landshamer S, Wagner E, Culmsee C (2007) Delayed neuronal death after brain trauma involves p53-dependent inhibition of NF-kappaB transcriptional activity. Cell Death Differ 14(8):1529-1541
17. Green DR, Kroemer G (2009) Cytoplasmic functions of the tumour suppressor p53. Nature 458(7242):1127-1130
18. Vaseva AV, Marchenko ND, Ji K, Tsirka SE, Holzmann S, Moll UM (2012) p53 opens the mitochondrial permeability transition pore to trigger necrosis. Cell 149(7):1536-1548
19. Nijboer CH, Heijnen CJ, van der Kooij MA, Zijlstra J, van Velthoven CTJ, Culmsee C, van Bel F, Hagberg H, Kavelaars A (2011) Targeting the p53 pathway to protect the neonatal ischemic brain. Ann Neurol 70(2):255-264
20. Culmsee C, Zhu X, Yu QS, Chan SL, Camandola S, Guo Z, Greig NH, Mattson MP (2001) A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid beta-peptide. J Neurochem 77(1):220-228
21. Zhu G, Wang X, Wu S, Li Q (2012) Involvement of activation of PI3K/Akt pathway in the protective effects of puerarin against MPP+-induced human neuroblastoma SH-SY5Y cell death. Neurochem Int 60(4):400-408
22. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV, Gudkov AV (1999) A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285(5434):1733-1737
23. Duan W, Zhu X, Ladenheim B, Yu Q, Guo Z, Oyler J, Cutler RG, Cadet JL, Greig NH, Mattson MP (2002) p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism. Ann Neurol 52(5):597-606
24. Chou J, Greig NH, Reiner D, Hoffer BJ, Wang Y (2011) Enhanced survival of dopaminergic neuronal transplants in hemiparkinsonian rats by the p53 inactivator PFT-α. Cell Transpl 20(9):1351-1359
25. Engel T, Murphy BM, Hatazaki S, Jimenez-Mateos EM, Concannon CG, Woods I, Prehn JHM, Henshall DC (2010) Reduced hippocampal damage and epileptic seizures after status epilepticus in mice lacking proapoptotic Puma. FASEB J 24(3):853-861
26. Hoagland MS, Hoagland EM, Swanson HI (2005) The p53 inhibitor pifithrin-alpha is a potent agonist of the aryl hydrocarbon receptor. J Pharmacol Exp Ther 314(2):603-610
27. Murphy PJM, Galigniana MD, Morishima Y, Harrell JM, Kwok RPS, Ljungman M, Pratt WB (2004) Pifithrin-alpha inhibits p53 signaling after interaction of the tumor suppressor protein with hsp90 and its nuclear translocation. J Biol Chem 279(29):30195-30201
28. Komarova EA, Neznanov N, Komarov PG, Chernov MV, Wang K, Gudkov AV (2003) p53 inhibitor pifithrin alpha can suppress heat shock and glucocorticoid signaling pathways. J Biol Chem 278(18):15465-15468
29. Schutte B, Nuydens R, Geerts H, Ramaekers F (1998) Annexin V binding assay as a tool to measure apoptosis in differentiated neuronal cells. J Neurosci Methods 86(1):63-69
30. Grohm J, Kim S, Mamrak U, Tobaben S, Cassidy-Stone A, Nunnari J, Plesnila N, Culmsee C (2012) Inhibition of Drp1 provides neuroprotection in vitro and in vivo. Cell Death Differ 19(9):1446-1458
31. Tan S, Sagara Y, Liu Y, Maher P, Schubert D (1998) The regulation of reactive oxygen species production during programmed cell death. J Cell Biol 141(6):1423-1432
32. Li Y, Maher P, Schubert D (1997) A role for 12-lipoxygenase in nerve cell death caused by glutathione depletion. Neuron 19(2):453-463
33. Vousden KH (2000) p53: death star. Cell 103(5):691-694
34. Rocha S, Campbell KJ, Roche KC, Perkins ND (2003) The p53-inhibitor pifithrin-alpha inhibits firefly luciferase activity in vivo and in vitro. BMC Mol Biol 4:9
35. Yonekura I, Takai K, Asai A, Kawahara N, Kirino T (2006) p53 potentiates hippocampal neuronal death caused by global ischemia. J Cereb Blood Flow Metab 26(10):1332-1340
36. Crumrine RC, Thomas AL, Morgan PF (1994) Attenuation of p53 expression protects against focal ischemic damage in transgenic mice. J Cereb Blood Flow Metab 14(6):887-891
37. Rieker C, Engblom D, Kreiner G, Domanskyi A, Schober A, Stotz S, Neumann M, Yuan X, Grummt I, Schütz G, Parlato R (2011) Nucleolar disruption in dopaminergic neurons leads to oxidative damage and parkinsonism through repression of mammalian target of rapamycin signaling. J Neurosci 31(2):453-460
38. Kreiner G, Bierhoff H, Armentano M, Rodriguez-Parkitna J, Sowodniok K, Naranjo JR, Bonfanti L, Liss B, Schütz G, Grummt I, Parlato R (2013) A neuroprotective phase precedes striatal degeneration upon nucleolar stress. Cell Death Differ 20(11):1455-1464
39. Mendjargal A, Odkhuu E, Koide N, Nagata H, Kurokawa T, Nonami T, Yokochi T (2013) Pifithrin-α, a pharmacological inhibitor of p53, downregulates lipopolysaccharide-induced nitric oxide production via impairment of the MyD88-independent pathway. Int Immunopharmacol 15(4):671-678
40. Gilman CP, Chan SL, Guo Z, Zhu X, Greig N, Mattson MP (2003) p53 is present in synapses where it mediates mitochondrial dysfunction and synaptic degeneration in response to DNA damage, and oxidative and excitotoxic insults. Neuromol Med 3(3):159-172
41. Duan W, Li Q, Xia M, Tashiro S, Onodera S, Ikejima T (2011) Silibinin activated p53 and induced autophagic death in human fibrosarcoma HT1080 cells via reactive oxygen species-p38 and c-Jun N-terminal kinase pathways. Biol Pharm Bull 34(1):47-53
42. Strom E, Sathe S, Komarov PG, Chernova OB, Pavlovska I, Shyshynova I, Bosykh DA, Burdelya LG, Macklis RM, Skaliter R, Komarova EA, Gudkov AV (2006) Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nat Chem Biol 2(9):474-479
43. Beckerman R, Prives C (2010) Transcriptional regulation by p53. Cold Spring Harb Perspect Biol 2(8):a000935
44. Toledo F, Wahl GM (2006) Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 6(12):909-923
45. Yu J, Wang Z, Kinzler KW, Vogelstein B, Zhang L (2003) PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc Natl Acad Sci USA 100(4):1931-1936
46. Yu J, Zhang L (2005) The transcriptional targets of p53 in apoptosis control. Biochem Biophys Res Commun 331(3):851-858
47. Leker RR, Aharonowiz M, Greig NH, Ovadia H (2004) The role of p53-induced apoptosis in cerebral ischemia: effects of the p53 inhibitor pifithrin alpha. Exp Neurol 187(2):478-486
48. Nakano K, Vousden KH (2001) PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 7(3):683-694
49. Niizuma K, Endo H, Nito C, Myer DJ, Chan PH (2009) Potential role of PUMA in delayed death of hippocampal CA1 neurons after transient global cerebral ischemia. Stroke 40(2):618-625
50. Jansson M, Durant ST, Cho E, Sheahan S, Edelmann M, Kessler B, La T, Nicholas B (2008) Arginine methylation regulates the p53 response. Nat Cell Biol 10(12):1431-1439
51. Diemert S, Dolga AM, Tobaben S, Grohm J, Pfeifer S, Oexler E, Culmsee C (2012) Impedance measurement for real time detection of neuronal cell death. J Neurosci Methods 203(1):69-77
52. Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, Kinzler KW, Vogelstein B (1997) 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1(1):3-11